Publications 2013
174.
Frantzi M, Metzger J, Banks RE, Husi H, Klein J, Dakna M, Mullen W, Cartledge JJ, Schanstra JP, Brand K, Kuczyk MA, Mischak H, Vlahou A, Theodorescu D, Merseburger AS.
Discovery and Validation of Urinary Biomarkers for Detection of Renal Cell Carcinoma.
J Proteomics. 2013 Dec 24. pii: S1874-3919(13)00645-3. doi: 10.1016/j.jprot.2013.12.010. [Epub ahead of print]
173.
Klein J, Papadopoulos T, Mischak H, Mullen W.
Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine.
Electrophoresis. 2013 Oct 8. doi: 10.1002/elps.201300327. [Epub ahead of print]
172.
Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, Mourad G, Daurès JP, Weinberger KM, Argilés A.
Plasma and Urinary Amino Acid Metabolomic Profiling in Patients with Different Levels of Kidney Function.
Clin J Am Soc Nephrol. 2013 Nov 14. [Epub ahead of print]
171.
Mermelekas G, Makridakis M, Koeck T, Vlahou A.
Redox proteomics: from residue modifications to putative biomarker identification by gel- and LC-MS-based approaches.
PMID: 24206227 [PubMed - in process]
170.
Husi H, Sanchez-Niño MD, Delles C, Mullen W, Vlahou A, Ortiz A, Mischak H.
A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI.
BMC Syst Biol. 2013 Oct 30;7(1):110. [Epub ahead of print]
169.
Dissard R, Klein J, Caubet C, Breuil B, Siwy J, Hoffman J, Sicard L, Ducassé L, Rascalou S, Payre B, Buléon M, Mullen W, Mischak H, Tack I, Bascands JL, Buffin-Meyer B, Schanstra JP.
Long Term Metabolic Syndrome Induced by a High Fat High Fructose Diet Leads to Minimal Renal Injury in C57BL/6 Mice.
PLoS One. 2013 Oct 3;8(10):e76703.
168.
Neuhaus J, Schiffer E, Siwy J, Mannello F, Horn LC, Stolzenburg JU
Proteome-based diagnostic and prognostic biomarkers of prostate cancer.
Urologe A. 2013 Sep;52(9):1251-5. doi: 10.1007/s00120-013-3308-0.
167.
Latosinska A, Frantzi M, Vlahou A, Mischak H
Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.
Proteomics Clin Appl. 2013 Aug 23. doi: 10.1002/prca.201300038. [Epub ahead of print]
166.
Klein J, Lacroix C, Caubet C, Siwy J, Zürbig P, Dakna M, Muller F, Breuil B, Stalmach A, Mullen W, Mischak H, Bandin F, Monsarrat B, Bascands JL, Decramer S, Schanstra JP.
Fetal Urinary Peptides to Predict Postnatal Outcome of Renal Disease in Fetuses with Posterior Urethral Valves (PUV).
Sci Transl Med. 2013 Aug 14;5(198):198ra106. doi: 10.1126/scitranslmed.3005807.
165.
Albalat A, Stalmach A, Bitsika V, Siwy J, Schanstra JP, Petropoulos AD, Vlahou A, Jankowski J, Persson F, Rossing P, Jaskolla TW, Mischak H, Husi H.
Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment.
Proteomics. 2013 Aug 14. doi: 10.1002/pmic.201300100. [Epub ahead of print]
164.
Frantzi M, Zoidakis J, Papadopoulos T, Zurbig P, Katafigiotis I, Stravodimos K, Lazaris A, Giannopoulou I, Ploumidis A, Mischak H, Mullen WB, Vlahou A.
IMAC fractionation in combination to LC/MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers.
J Proteome Res. 2013 Sep 6;12(9):3969-79. doi: 10.1021/pr400255h. Epub 2013 Aug 21.
163.
Weissinger EM, Metzger J, Dobbelstein C, Wolff D, Schleuning M, Kuzmina Z, Greinix H, Dickinson AM, Mullen W, Kreipe H, Hamwi I, Morgan M, Krons A, Tchebotarenko I, Ihlenburg-Schwarz D, Dammann E, Collin M, Ehrlich S, Diedrich H, Stadler M, Eder M, Holler E, Mischak H, Krauter J, Ganser A.
Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host-disease after allogeneic stem cell transplantation.
Leukemia. 2013 Jul 11. doi: 10.1038/leu.2013.210. [Epub ahead of print]
162.
Suárez ER, Siwy J, Zürbig P, Mischak H.
Urine as a source for clinical proteome analysis: From discovery to clinical application.
Biochim Biophys Acta. 2013 Jul 2. pii: S1570-9639(13)00253-7. doi: 10.1016/j.bbapap.2013.06.016. [Epub ahead of print]
161.
Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy J, Ulrici W, Paasch U, Horn LC, Stolzenburg J
Seminal Plasma as a Source of Prostate Cancer Peptide Biomarker Candidates for Detection of Indolent and Advanced Disease
PLoS ONE 8(6): e67514. doi:10.1371/journal.pone.0067514
160.
Klein G, Schanstra JP, Hoffmann J, Mischak H, Siwy J
Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products
PLoS ONE 8(6): e66682. doi:10.1371/journal.pone.0066682
159.
Argilés A, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM, Mischak H.
CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis.
PLoS One. 2013 May 14;8(5):e62837. doi: 10.1371/journal.pone.0062837. Print 2013.
158.
Jankowski V, Schulz A, Kretschmer A, Mischak H, Boehringer F, van der Giet M, Janke D, Schuchardt M, Herwig R, Zidek W, Jankowski J.
The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates.
J Mol Med (Berl). 2013 Sep;91(9):1095-107. doi: 10.1007/s00109-013-1036-y. Epub 2013 May 1.
157.
Mansor R, Mullen W, Albalat A, Zerefos P, Mischak H, Barrett DC, Biggs A, Eckersall PD
A peptidomic approach to biomarker discovery for bovine mastitis.
J Proteomics. 2013 Jun 24;85:89-98. doi: 10.1016/j.jprot.2013.04.027. Epub 2013 Apr 30.
156.
Stalmach A, Albalat A, Mullen W, Mischak H.
Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.
Electrophoresis. 2013 Jun;34(11):1452-64. doi: 10.1002/elps.201200708. Epub 2013 May 8.
155.
Mischak H, Vlahou A, Ioannidis JP.
Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience.
Clin Biochem. 2013 Apr;46(6):432-43. doi: 10.1016/j.clinbiochem.2012.09.025. Epub 2012 Oct 4.
154.
Klein J, Eales J, Zürbig P, Vlahou A, Mischak H, Stevens R.
Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally-occurring peptide generation.
Proteomics. 2013 Apr;13(7):1077-82. doi: 10.1002/pmic.201200493. Epub 2013 Feb 26.
View Abstract Request Reprint
153.
Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
PLoS One. 2013;8(1):e53016. doi: 10.1371/journal.pone.0053016. Epub 2013 Jan 10.
View Abstract Request Reprint
152.
Albalat A, Franke J, Gonzalez J, Mischak H, Zürbig P.
Urinary proteomics based on capillary electrophoresis coupled to mass spectrometry in kidney disease.
Methods Mol Biol. 2013;919:203-13.
View Abstract Request Reprint
151.
Metzger J, Negm AA, Plentz RR, Weismüller TJ, Wedemeyer J, Karlsen TH, Dakna M, Mullen W, Mischak H, Manns MP, Lankisch TO
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders
Gut. 2013 Jan;62(1):122-30. doi: 10.1136/gutjnl-2012-302047. Epub 2012 May 12.
150.
Roscioni SS, de Zeeuw D, Hellemons ME, Mischak H, Zürbig P, Bakker SJ, Gansevoort RT, Reinhard H, Persson F, Lajer M, Rossing P, Heerspink HJ.
A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.
Diabetologia. 2013 Feb;56(2):259-67. doi: 10.1007/s00125-012-2755-2. Epub 2012 Oct 20.